• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Prospects for developing Biomedical Cellular Products in the Russian Federation.

22.04.2021/in Publications /by Marketing

Biomedical cellular product (BMCP) is a complex comprising cell line(s) and excipients or cell line(s) and excipients in combination with state-registered medicinal products for medical use (hereinafter – medicinal products) and (or) medical devices.  a Biomedical Cellular Product is a product that contains cultured human cells.  It divided biomedical cell products into several types: autologous (derived from the patient’s cells), allogeneic (derived from the cells of another person) and combined (derived from several people). With autologous products, BMCPs are being developed to treat musculoskeletal diseases (e.g., to repair cartilage damage to the joint surface), ophthalmology, cancer, and other diseases.

According to the FDA, there are17 BMCPs registered. The European Medicines Evaluation Agency’s database contains information on 16 BMCPs, and it has registered only four drugs in both the U.S. and the European Union. These BMCPs are intended to treat oncological diseases.

The Federal Law N 180-FZ “On Biomedical Cellular Products” was adopted in 2016 In Russia. In this article, we will look at the specifics of conducting clinical trials of biomedical cell products (BMCPs), as well as assess the prospects for the development of BMCPs in Russia.

Conducting clinical trials of BMCPs.

There is clinical trials of biomedical cell products in medical institutions accredited by the Russian Ministry of Health. The requirements for a medical organization to be accredited to conduct clinical trials of biomedical cellular products are:

  • availability of a license to conduct medical activities;
  • availability of intensive care and intensive care unit (wards) in case of clinical trials of biomedical cellular products to determine safety, tolerability, and efficacy of biomedical cellular products;
  • availability of copies of regulatory legal acts governing the organization and conduct of clinical trials of biomedical cell products;
  • ensuring the confidentiality of personal data of patients taking part in clinical trials of biomedical cell products;
  • compliance with the rules of good clinical practice for biomedical cell products.

As with clinical trials of pharmaceuticals, if it detects any danger to the life and health of patients in conducting a clinical trial of a biomedical cell product, the head of a medical organization may suspend the trial. An allowed federal agency shall decide to suspend such research based on a written communication from the head of the medical organization in which the clinical trial of the biomedical cell product is being conducted.

A report on the results of a clinical trial of a biomedical cell product is prepared by the organizer of the clinical trial of the biomedical cell product and is submitted to the allowed federal executive body which issued the permission to conduct the trial, within three months from its completion.

According to the Appendix to the Order of the Ministry of Health of the Russian Federation of May 31, 2017. N 279n, the register of issued approvals to conduct clinical trials of biomedical cell products must contain the following information:

  1. the number of the registry entry and the date of inclusion in the registry of information about the authorization issued to conduct a clinical trial of a biomedical cellular product;
  2. date and number of permission to conduct a clinical trial of a biomedical cell product;
  3. name and location address of the organization organizing the clinical trial of a biomedical cell product;
  4. name of the legal entity engaged by the organization referred to in subparagraph 3 of this paragraph to organize the conduct of the clinical trial of a biomedical cell product (if any);
  5. name of the biomedical cell product;
  6. name of the protocol of clinical trial of a biomedical cell product;
  7. purpose of the clinical trial of biomedical cell product;
  8. terms of the clinical trial of biomedical cell product; 9) number of patients taking part in the clinical trial of biomedical cell product;
  9. number of patients taking part in a clinical trial of a biomedical cell product;
  10. list of medical organizations where clinical trials of biomedical cell product are supposed to be carried out, with the sign of location addresses and places of activity;
  11. the current status of clinical trials of biomedical cell products (ongoing, completed, suspended, ended).

As of today, the registry of issued approvals to conduct clinical trials of biomedical cell products is not freely available on the website of the Russian Ministry of Health.

The list of medical organizations accredited to conduct clinical trials of biomedical cell products is on the website of the State Registry of Medicines https://grls.rosminzdrav.ru/.

The procedure for introducing BMCPs into the Russian market is quite time-consuming, lengthy, and requires serious financial expenses. According to experts, preclinical and clinical trials of BMCPs can take 9-11 years. The personnel issue also remains an open one. Pharmaceutical companies and research centers conduct training courses aimed at increasing the level of professionalism in this field.

Development of biomedical cell products in RF.

Roszdravnadzor issued Russia’s first license for the production of biomedical cellular products in 2020. Generium JSC is the only production site in Russia that has received a license to manufacture biomedical cellular products. Under the current license, Generium JSC plans to develop and produce several unique autologous, allogeneic and combined BMCP, as well as personalized therapy and diagnostic tools, including those aimed at fighting the pandemic coronavirus infection (COVID-19).

Russia is still at the initial stage of developing biomedical cellular products. It is necessary to continue improving the legal and regulatory framework, ensure quality training of specialists at all stages of work, create an association of BMCP producers, and prepare the infrastructure. Besides, it will be useful to turn to foreign experience in the development and implementation of BMPCs, because there are already about 30 registered preparations based on cell technology on the world market

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 6 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Bioequivalence studies during the COVID-19 pandemic. Russian experience. Early access programs for patients to non-registered drugs
Scroll to top